{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:30:46Z","timestamp":1792801846411,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13555-026-01735-9","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:20:19Z","timestamp":1775031619000},"page":"2343-2362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterization and Management of Androgenetic Alopecia in Transgender and Gender-Diverse Individuals: A Narrative Review"],"prefix":"10.1007","volume":"16","author":[{"given":"Daniel","family":"Ramos-Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sanchez-Baez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cabrera-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Perez-Bustillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Hermosa-Gelbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Va\u00f1o-Galvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saceda-Corralo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6190-0147","authenticated-orcid":false,"given":"Juan","family":"Jimenez-Cauhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"4","key":"1735_CR1","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jaad.2021.08.067","volume":"89","author":"JL Gao","year":"2023","unstructured":"Gao JL, Streed CG, Thompson J, Dommasch ED, Peebles JK. Androgenetic alopecia in transgender and gender diverse populations: a review of therapeutics. J Am Acad Dermatol. 2023;89(4):774\u201383. https:\/\/doi.org\/10.1016\/j.jaad.2021.08.067.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1735_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jamadermatol.2020.5475","volume":"157","author":"N Thoreson","year":"2021","unstructured":"Thoreson N, Grasso C, Potter J, King DS, Peebles JK, Dommasch ED. Incidence and factors associated with androgenetic alopecia among transgender and gender-diverse patients treated with masculinizing hormone therapy. JAMA Dermatol. 2021;157(3):348\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2020.5475.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1735_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/bjd.18099","volume":"181","author":"DH Marks","year":"2019","unstructured":"Marks DH, Hagigeorges D, Manatis-Lornell AJ, Dommasch E, Senna MM. Hair loss among transgender and gender-nonbinary patients: a cross-sectional study. Br J Dermatol. 2019;181(5):1082\u20133. https:\/\/doi.org\/10.1111\/bjd.18099.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1735_CR4","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jaad.2023.01.037","volume":"89","author":"JL Gao","year":"2023","unstructured":"Gao JL, Sanz J, Tan N, King DS, Modest AM, Dommasch ED. Androgenetic alopecia incidence in transgender and gender diverse populations: a retrospective comparative cohort study. J Am Acad Dermatol. 2023;89(3):504\u201310. https:\/\/doi.org\/10.1016\/j.jaad.2023.01.037.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"1735_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","volume":"23","author":"E Coleman","year":"2022","unstructured":"Coleman E, Radix AE, Bouman WP, et\u00a0al. Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health. 2022;23(Suppl 1):S1\u2013259. https:\/\/doi.org\/10.1080\/26895269.2022.2100644.","journal-title":"Int J Transgend Health"},{"issue":"6","key":"1735_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/01.med.0000436182.42966.31","volume":"20","author":"I Esteva de Antonio","year":"2013","unstructured":"Esteva de Antonio I, G\u00f3mez-Gil E, GIDSEEN Group. Coordination of healthcare for transsexual persons: a multidisciplinary approach. Curr Opin Endocrinol Diabetes Obes. 2013;20(6):585\u201391. https:\/\/doi.org\/10.1097\/01.med.0000436182.42966.31.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"6","key":"1735_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.endonu.2012.02.001","volume":"59","author":"O Moreno-P\u00e9rez","year":"2012","unstructured":"Moreno-P\u00e9rez O, Esteva De Antonio I, Grupo de Identidad y Diferenciaci\u00f3n Sexual de la SEEN (GIDSEEN). [Clinical practice guidelines for assessment and treatment of transsexualism. SEEN Identity and Sexual Differentiation Group (GIDSEEN)]. Endocrinol Nutr. 2012;59(6):367\u201382. https:\/\/doi.org\/10.1016\/j.endonu.2012.02.001.","journal-title":"Endocrinol Nutr"},{"issue":"5","key":"1735_CR8","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s13555-021-00574-0","volume":"11","author":"CC Motosko","year":"2021","unstructured":"Motosko CC, Tosti A. Dermatologic care of hair in transgender patients: a systematic review of literature. Dermatol Ther (Heidelb). 2021;11(5):1457\u201368. https:\/\/doi.org\/10.1007\/s13555-021-00574-0.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1735_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1089\/trgh.2021.0105","volume":"8","author":"S Rutnin","year":"2023","unstructured":"Rutnin S, Suchonwanit P, Kositkuljorn C, et\u00a0al. Characterizing dermatological conditions in the transgender population: a cross-sectional study. Transgend Health. 2023;8(1):89\u201399. https:\/\/doi.org\/10.1089\/trgh.2021.0105.","journal-title":"Transgend Health"},{"issue":"2","key":"1735_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1096\/fj.201700260RR","volume":"32","author":"BH Miranda","year":"2018","unstructured":"Miranda BH, Charlesworth MR, Tobin DJ, Sharpe DT, Randall VA. Androgens trigger different growth responses in genetically identical human hair follicles in organ culture that reflect their epigenetic diversity in life. FASEB J. 2018;32(2):795\u2013806. https:\/\/doi.org\/10.1096\/fj.201700260RR.","journal-title":"FASEB J"},{"issue":"1","key":"1735_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1089\/trgh.2016.0022","volume":"1","author":"MO Stevenson","year":"2016","unstructured":"Stevenson MO, Wixon N, Safer JD. Scalp hair regrowth in hormone-treated transgender woman. Transgend Health. 2016;1(1):202\u20134. https:\/\/doi.org\/10.1089\/trgh.2016.0022.","journal-title":"Transgend Health"},{"issue":"3","key":"1735_CR12","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.jaad.2011.10.017","volume":"67","author":"P Adenuga","year":"2012","unstructured":"Adenuga P, Summers P, Bergfeld W. Hair regrowth in a male patient with extensive androgenetic alopecia on estrogen therapy. J Am Acad Dermatol. 2012;67(3):e121-123. https:\/\/doi.org\/10.1016\/j.jaad.2011.10.017.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1735_CR13","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.jaad.2025.01.087","volume":"92","author":"GT Tang","year":"2025","unstructured":"Tang GT, Sinclair R, Leemaqz S, Cheung AS. Scalp hair parameter changes in transgender individuals commencing gender-affirming hormone therapy: a 24-week prospective observational study. J Am Acad Dermatol. 2025;92(6):1390\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2025.01.087.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1735_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jaad.2025.08.061","volume":"94","author":"D Ramos-Rodr\u00edguez","year":"2026","unstructured":"Ramos-Rodr\u00edguez D, Sanchez-Baez D, Garcia PC, et\u00a0al. Use of oral minoxidil for androgenetic alopecia in transgender and gender-diverse people. A retrospective study of 27 patients. J Am Acad Dermatol. 2026;94(1):215\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.061.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1735_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/jvc2.53","volume":"1","author":"M Dominguez-Santas","year":"2022","unstructured":"Dominguez-Santas M, Diaz-Guimaraens B, Saceda-Corralo D, et\u00a0al. The state-of-the-art in the management of androgenetic alopecia: a review of new therapies and treatment algorithms. JEADV Clin Pract. 2022;1(3):176\u201385. https:\/\/doi.org\/10.1002\/jvc2.53.","journal-title":"JEADV Clin Pract"},{"issue":"5","key":"1735_CR16","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s13555-023-00919-x","volume":"13","author":"Z Shadi","year":"2023","unstructured":"Shadi Z. Compliance to topical minoxidil and reasons for discontinuation among patients with androgenetic alopecia. Dermatol Ther (Heidelb). 2023;13(5):1157\u201369. https:\/\/doi.org\/10.1007\/s13555-023-00919-x.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1735_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.725269","volume":"12","author":"KC Pang","year":"2021","unstructured":"Pang KC, Nguyen TP, Upreti R. Case report: Successful use of minoxidil to promote facial hair growth in an adolescent transgender male. Front Endocrinol (Lausanne). 2021;12:725269. https:\/\/doi.org\/10.3389\/fendo.2021.725269.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"1735_CR18","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1007\/s40618-024-02373-8","volume":"47","author":"L Marinelli","year":"2024","unstructured":"Marinelli L, Bichiri A, Cagnina S, Castella L, Ghigo E, Motta G. Efficacy of topical minoxidil in enhancing beard growth in a group of transgender assigned female at birth individuals on gender affirming hormone therapy. J Endocrinol Invest. 2024;47(11):2843\u201350. https:\/\/doi.org\/10.1007\/s40618-024-02373-8.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"1735_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.36849\/jdd.7519","volume":"23","author":"E Sanfilippo","year":"2024","unstructured":"Sanfilippo E, Friedman A. Survey of dermatology practitioners\u2019 opinions and prescribing habits of oral minoxidil for the treatment of androgenetic alopecia. J Drugs Dermatol. 2024;23(3):136\u201340. https:\/\/doi.org\/10.36849\/jdd.7519.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1735_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/ajd.14098","volume":"64","author":"A Willems","year":"2023","unstructured":"Willems A, Moussa A, Sinclair R. Australian dermatologists\u2019 prescribing behaviours for male androgenetic alopecia. Australas J Dermatol. 2023;64(3):429\u201332. https:\/\/doi.org\/10.1111\/ajd.14098.","journal-title":"Australas J Dermatol"},{"issue":"6","key":"1735_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14061805","volume":"14","author":"J Jimenez-Cauhe","year":"2025","unstructured":"Jimenez-Cauhe J, Lo Sicco KI, Shapiro J, et\u00a0al. Characterization and management of adverse events of low-dose oral minoxidil treatment for alopecia: a narrative review. J Clin Med. 2025;14(6):1805. https:\/\/doi.org\/10.3390\/jcm14061805.","journal-title":"J Clin Med"},{"key":"1735_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2023.10.013","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2024","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, Fernandez-Crehuet P, Garnacho G, et\u00a0al. Recomendaciones sobre el manejo cl\u00ednico de la alopecia androg\u00e9nica: un documento de consenso del Grupo Espa\u00f1ol de Tricolog\u00eda de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda. Actas Dermosifiliogr. 2024. https:\/\/doi.org\/10.1016\/j.ad.2023.10.013.","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"1735_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/ijt.ijt_70_23","volume":"15","author":"K Godse","year":"2023","unstructured":"Godse K, De A, Vedamurthy M, et\u00a0al. Low-dose oral minoxidil in the treatment of alopecia: evidence and experience-based consensus statement of Indian experts. Int J Trichology. 2023;15(3):91\u20137. https:\/\/doi.org\/10.4103\/ijt.ijt_70_23.","journal-title":"Int J Trichology"},{"issue":"5","key":"1735_CR24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.abd.2023.08.016","volume":"99","author":"BD Sanabria","year":"2024","unstructured":"Sanabria BD, Perdomo YC, Miot HA, Ramos PM. Oral minoxidil 7.5\u202fmg for hair loss increases heart rate with no change in blood pressure in 24 h Holter and 24 h ambulatory blood pressure monitoring. An Bras Dermatol. 2024;99(5):734\u20136. https:\/\/doi.org\/10.1016\/j.abd.2023.08.016.","journal-title":"An Bras Dermatol"},{"issue":"7","key":"1735_CR25","doi-asserted-by":"publisher","first-page":"T769","DOI":"10.1016\/j.ad.2025.05.018","volume":"116","author":"OM Moreno-Arrones","year":"2025","unstructured":"Moreno-Arrones OM, Hermosa-Gelbard A, Saceda-Corralo D, et\u00a0al. High-dose oral minoxidil for the treatment of androgenetic alopecia [Translated article] . Actas Dermosifiliogr. 2025;116(7):T769\u201372. https:\/\/doi.org\/10.1016\/j.ad.2025.05.018.","journal-title":"Actas Dermosifiliogr"},{"issue":"4","key":"1735_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.jaad.2025.06.029","volume":"93","author":"D Zaminski","year":"2025","unstructured":"Zaminski D, Zampella JG, Shapiro J, Lo Sicco KI, Mazori DR. Use of low-dose oral minoxidil for hair growth in transgender and gender nonbinary adult patients: a retrospective cohort study. J Am Acad Dermatol. 2025;93(4):1126\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2025.06.029.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1735_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13182","volume":"33","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2020","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, Saceda-Corralo D, Moreno-Arrones OM, et\u00a0al. Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: a descriptive monocentric study. Dermatol Ther. 2020;33(1):e13182. https:\/\/doi.org\/10.1111\/dth.13182.","journal-title":"Dermatol Ther"},{"key":"1735_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2147\/CIA.S192435","volume":"14","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clin Interv Aging. 2019;14:399\u2013406. https:\/\/doi.org\/10.2147\/CIA.S192435.","journal-title":"Clin Interv Aging"},{"issue":"3","key":"1735_CR29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/jamadermatol.2021.5743","volume":"158","author":"AK Gupta","year":"2022","unstructured":"Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative efficacy of minoxidil and the 5-\u03b1 reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatol. 2022;158(3):266\u201374. https:\/\/doi.org\/10.1001\/jamadermatol.2021.5743.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1735_CR30","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1111\/andr.12881","volume":"9","author":"MS Irwig","year":"2021","unstructured":"Irwig MS. Is there a role for 5\u03b1-reductase inhibitors in transgender individuals? Andrology. 2021;9(6):1729\u201331. https:\/\/doi.org\/10.1111\/andr.12881.","journal-title":"Andrology"},{"issue":"11","key":"1735_CR31","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1210\/jc.2017-01658","volume":"102","author":"WC Hembree","year":"2017","unstructured":"Hembree WC, Cohen-Kettenis PT, Gooren L, et\u00a0al. Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869\u2013903. https:\/\/doi.org\/10.1210\/jc.2017-01658.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1735_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-8587(16)00036-X","volume":"5","author":"MS Irwig","year":"2017","unstructured":"Irwig MS. Testosterone therapy for transgender men. Lancet Diabetes Endocrinol. 2017;5(4):301\u201311. https:\/\/doi.org\/10.1016\/S2213-8587(16)00036-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"1735_CR33","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.ad.2023.05.046","volume":"115","author":"OM Moreno-Arrones","year":"2024","unstructured":"Moreno-Arrones OM, Saceda-Corralo D, Ortega-Quijano D, Hermosa-Gelbard A, Va\u00f1\u00f3-Galv\u00e1n S. Impact of finasteride and dutasteride in beard thickness in men with androgenetic alopecia: a 453-patient retrospective trial. Actas Dermosifiliogr. 2024;115(10):1015\u20136. https:\/\/doi.org\/10.1016\/j.ad.2023.05.046.","journal-title":"Actas Dermosifiliogr"},{"issue":"8","key":"1735_CR34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/ajd.14359","volume":"65","author":"A Lyakhovitsky","year":"2024","unstructured":"Lyakhovitsky A, Amichai B, Galili E, et\u00a0al. The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia and androgenetic alopecia: a population-based case-control study. Australas J Dermatol. 2024;65(8):621\u20139. https:\/\/doi.org\/10.1111\/ajd.14359.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"1735_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.70102","volume":"24","author":"AK Gupta","year":"2025","unstructured":"Gupta AK, Bamimore MA, Williams G, Talukder M. Finasteride use: evaluation of depression and suicide risk. J Cosmet Dermatol. 2025;24(3):e70102. https:\/\/doi.org\/10.1111\/jocd.70102.","journal-title":"J Cosmet Dermatol"},{"key":"1735_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.euros.2023.04.009","volume":"52","author":"H Al Saffar","year":"2023","unstructured":"Al Saffar H, Xu J, O\u2019Brien JS, Kelly BD, Murphy DG, Lawrentschuk N. US Food and Drug Administration warning regarding finasteride and suicidal ideation: what should urologists know? Eur Urol Open Sci. 2023;52:4\u20136. https:\/\/doi.org\/10.1016\/j.euros.2023.04.009.","journal-title":"Eur Urol Open Sci"},{"key":"1735_CR37","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jad.2020.05.074","volume":"274","author":"M Konrad","year":"2020","unstructured":"Konrad M, Kostev K. Increased prevalence of depression, anxiety, and adjustment and somatoform disorders in transsexual individuals. J Affect Disord. 2020;274:482\u20135. https:\/\/doi.org\/10.1016\/j.jad.2020.05.074.","journal-title":"J Affect Disord"},{"issue":"7","key":"1735_CR38","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/ced.13184","volume":"42","author":"OM Moreno-Arrones","year":"2017","unstructured":"Moreno-Arrones OM, Becerra A, Vano-Galvan S. Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients. Clin Exp Dermatol. 2017;42(7):743\u20138. https:\/\/doi.org\/10.1111\/ced.13184.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1735_CR39","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s13256-025-05562-y","volume":"19","author":"Y Tominaga","year":"2025","unstructured":"Tominaga Y, Kobayashi T, Matsumoto Y, et\u00a0al. The safety and efficacy of finasteride for transgender men with androgenetic alopecia: a case series. J Med Case Rep. 2025;19(1):468. https:\/\/doi.org\/10.1186\/s13256-025-05562-y.","journal-title":"J Med Case Rep"},{"issue":"1","key":"1735_CR40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/ced.14847","volume":"47","author":"KM Babbush","year":"2022","unstructured":"Babbush KM, Andriano TM, Cohen SR. Antiandrogen therapy in hidradenitis suppurativa: finasteride for females. Clin Exp Dermatol. 2022;47(1):86\u201392. https:\/\/doi.org\/10.1111\/ced.14847.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1735_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1468-3083.2010.03758.x","volume":"25","author":"JH Yeon","year":"2011","unstructured":"Yeon JH, Jung JY, Choi JW, et\u00a0al. 5 mg\/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol. 2011;25(2):211\u20134. https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03758.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1735_CR42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1089\/trgh.2017.0035","volume":"3","author":"MC Leinung","year":"2018","unstructured":"Leinung MC, Feustel PJ, Joseph J. Hormonal treatment of transgender women with oral estradiol. Transgend Health. 2018;3(1):74\u201381. https:\/\/doi.org\/10.1089\/trgh.2017.0035.","journal-title":"Transgend Health"},{"issue":"4","key":"1735_CR43","first-page":"457","volume":"17","author":"SW Lee","year":"2018","unstructured":"Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 2018;17(4):457\u201363.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1735_CR44","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/jdv.17738","volume":"36","author":"BM Piraccini","year":"2022","unstructured":"Piraccini BM, Blume-Peytavi U, Scarci F, et\u00a0al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36(2):286\u201394. https:\/\/doi.org\/10.1111\/jdv.17738.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1735_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70237","author":"B Sanabria","year":"2025","unstructured":"Sanabria B, Medeiros MZ, Miot HA, M\u00fcller Ramos P. Monthly versus quarterly dutasteride mesotherapy for male androgenetic alopecia: a randomized trial. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70237.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1735_CR46","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.36849\/jdd.7653","volume":"23","author":"S Devjani","year":"2024","unstructured":"Devjani S, Ezemma O, Jothishankar B, Saberi S, Kelley KJ, Makredes Senna M. Efficacy of low-dose spironolactone for hair loss in women. J Drugs Dermatol. 2024;23(3):e91\u20132. https:\/\/doi.org\/10.36849\/jdd.7653.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1735_CR47","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.jaad.2020.10.097","volume":"84","author":"B Olamiju","year":"2021","unstructured":"Olamiju B, Craiglow BG. Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls. J Am Acad Dermatol. 2021;84(6):1689\u201391. https:\/\/doi.org\/10.1016\/j.jaad.2020.10.097.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1735_CR48","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaad.2021.07.048","volume":"86","author":"JF James","year":"2022","unstructured":"James JF, Jamerson TA, Aguh C. Efficacy and safety profile of oral spironolactone use for androgenic alopecia: a systematic review. J Am Acad Dermatol. 2022;86(2):425\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.048.","journal-title":"J Am Acad Dermatol"},{"key":"1735_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70060","author":"J Jimenez-Cauhe","year":"2025","unstructured":"Jimenez-Cauhe J, Gil-Redondo R, Saceda-Corralo D, et\u00a0al. Spironolactone and bicalutamide selectively reduce facial hypertrichosis induced by low-dose oral minoxidil. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70060.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1735_CR50","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/j.jaad.2024.12.048","volume":"92","author":"J Jimenez-Cauhe","year":"2025","unstructured":"Jimenez-Cauhe J, Gil-Redondo R, Saceda-Corralo D, et\u00a0al. Spironolactone reduces the risk of low-dose oral minoxidil-induced edema in women with female pattern hair loss. J Am Acad Dermatol. 2025;92(6):e197\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2024.12.048.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1735_CR51","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/j.jaad.2020.04.054","volume":"83","author":"D Fernandez-Nieto","year":"2020","unstructured":"Fernandez-Nieto D, Saceda-Corralo D, Jimenez-Cauhe J, et\u00a0al. Bicalutamide: a potential new oral antiandrogenic drug for female pattern hair loss. J Am Acad Dermatol. 2020;83(5):e355\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.054.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1735_CR52","doi-asserted-by":"publisher","first-page":"276","DOI":"10.4274\/jcrpe.galenos.2023.2023-1-13","volume":"15","author":"E Karak\u0131l\u0131\u00e7 \u00d6zturan","year":"2023","unstructured":"Karak\u0131l\u0131\u00e7 \u00d6zturan E, \u00d6zt\u00fcrk AP, Ba\u015f F, et\u00a0al. Endocrinological approach to adolescents with gender dysphoria: experience of a pediatric endocrinology department in a tertiary center in Turkey. J Clin Res Pediatr Endocrinol. 2023;15(3):276\u201384. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2023.2023-1-13.","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"1735_CR53","doi-asserted-by":"publisher","DOI":"10.1177\/20420188241305022","volume":"15","author":"LM Angus","year":"2024","unstructured":"Angus LM, Hong QV, Cheung AS, Nolan BJ. Effect of bicalutamide on serum total testosterone concentration in transgender adults: a case series. Ther Adv Endocrinol Metab. 2024;15:20420188241305022. https:\/\/doi.org\/10.1177\/20420188241305022.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"3","key":"1735_CR54","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/26895269.2023.2294321","volume":"25","author":"JS Fuqua","year":"2024","unstructured":"Fuqua JS, Shi E, Eugster EA. A retrospective review of the use of bicalutamide in transfeminine youth; a single center experience. Int J Transgender Health. 2024;25(3):533\u20137. https:\/\/doi.org\/10.1080\/26895269.2023.2294321.","journal-title":"Int J Transgender Health"},{"issue":"4","key":"1735_CR55","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jadohealth.2018.10.296","volume":"64","author":"A Neyman","year":"2019","unstructured":"Neyman A, Fuqua JS, Eugster EA. Bicalutamide as an androgen blocker with secondary effect of promoting feminization in male-to-female transgender adolescents. J Adolesc Health. 2019;64(4):544\u20136. https:\/\/doi.org\/10.1016\/j.jadohealth.2018.10.296.","journal-title":"J Adolesc Health"},{"issue":"3","key":"1735_CR56","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.fsc.2023.04.003","volume":"31","author":"A Bared","year":"2023","unstructured":"Bared A, Epstein JS. Gender-affirmation hair transplantation techniques. Facial Plast Surg Clin North Am. 2023;31(3):375\u201380. https:\/\/doi.org\/10.1016\/j.fsc.2023.04.003.","journal-title":"Facial Plast Surg Clin North Am"},{"issue":"3","key":"1735_CR57","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/PRS.0000000000003149","volume":"139","author":"L Capit\u00e1n","year":"2017","unstructured":"Capit\u00e1n L, Simon D, Meyer T, et\u00a0al. Facial feminization surgery: simultaneous hair transplant during forehead reconstruction. Plast Reconstr Surg. 2017;139(3):573\u201384. https:\/\/doi.org\/10.1097\/PRS.0000000000003149.","journal-title":"Plast Reconstr Surg"},{"issue":"12","key":"1735_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2025.106921","volume":"164","author":"A Franco-Moreno","year":"2025","unstructured":"Franco-Moreno A, Ryan P, Mu\u00f1oz-Rivas N, Valencia J, Torres-Macho J, Bacete-Cebri\u00e1n S. Risk of venous thromboembolism in the transgender population on hormone therapy: a systematic review. Med Clin (Barc). 2025;164(12):106921. https:\/\/doi.org\/10.1016\/j.medcli.2025.106921.","journal-title":"Med Clin (Barc)"},{"issue":"1","key":"1735_CR59","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1373\/clinchem.2018.288316","volume":"65","author":"J Khan","year":"2019","unstructured":"Khan J, Schmidt RL, Spittal MJ, Goldstein Z, Smock KJ, Greene DN. Venous thrombotic risk in transgender women undergoing estrogen therapy: a systematic review and metaanalysis. Clin Chem. 2019;65(1):57\u201366. https:\/\/doi.org\/10.1373\/clinchem.2018.288316.","journal-title":"Clin Chem"},{"issue":"1","key":"1735_CR60","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/jocd.15907","volume":"23","author":"A Ewulu","year":"2024","unstructured":"Ewulu A, Amibang R, Deng M. Review of hair prosthetic options for patients with alopecia. J Cosmet Dermatol. 2024;23(1):8\u201316. https:\/\/doi.org\/10.1111\/jocd.15907.","journal-title":"J Cosmet Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01735-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01735-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01735-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:18:33Z","timestamp":1779949113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01735-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1735"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01735-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Daniel Ramos-Rodr\u00edguez, Daniel Sanchez-Baez, Patricia Cabrera Garcia, Alicia P\u00e9rez-Bustillo, and Juan Jimenez-Cauhe have nothing to disclose. Angela Hermosa-Gelbard, Sergio Va\u00f1o-Galvan, and David Saceda-Corralo have received honoraria as speakers and\/or advisors from Lilly and Pfizer. David Saceda-Corralo is an Editorial Board member of\n                      Dermatology and Therapy\n                      . David Saceda-Corralo was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}